Oncotelic Therapeutics Featured in Editorial on AI’s Growing Role in Pharmaceutical Manufacturing

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in an editorial published by AINewsWire that examines the expanding integration of artificial intelligence within pharmaceutical manufacturing. The editorial describes a sector-wide movement toward incorporating AI directly into production workflows as a continuous compliance mechanism. This approach allows for real-time monitoring, validation, and optimization of manufacturing processes to address evolving Good Manufacturing Practice requirements.

The discussion positions companies like Oncotelic at the convergence of biotechnology and advanced digital systems, which are seen as key drivers for achieving scalable efficiency and long-term cost benefits in drug production. The editorial is part of the content network managed by IBN (InvestorBrandNetwork). The full press release detailing this feature is available online at https://ibn.fm/S3jjv.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company concentrating on developing products for oncology and immunotherapy. The company aims to tackle cancers with high unmet needs and rare pediatric conditions using innovative, late-stage therapeutic candidates. Beyond its internal drug development pipeline, Oncotelic leverages the extensive intellectual property portfolio of its CEO, Dr. Vuong Trieu, who has submitted over 500 patent applications and holds 75 issued U.S. patents.

The company also engages in licensing and co-development activities through joint ventures. Notably, Oncotelic owns a 45% stake in GMP Bio, a joint venture led by Dr. Trieu, which is progressing its own series of drug candidates. These external programs are intended to complement and reinforce Oncotelic’s strategic focus within oncology and rare disease therapeutics. Additional news and updates concerning OTLC can be accessed through the company’s newsroom at https://ibn.fm/OTLC.

AINewsWire operates as part of the Dynamic Brand Portfolio at IBN, which includes BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire distributes content through a network of wire solutions, editorial syndication to thousands of outlets, enhanced press release services, and social media distribution. The platform’s full terms of use and disclaimers are published on its website at https://www.BioMedWire.com/Disclaimer.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Featured in Editorial on AI’s Growing Role in Pharmaceutical Manufacturing.

The post Oncotelic Therapeutics Featured in Editorial on AI’s Growing Role in Pharmaceutical Manufacturing appeared first on citybuzz.